Please login to the form below

Not currently logged in
Email:
Password:

Cellectis gets FDA nod for 'off-the-shelf' CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

CellectisCellectis has been given the go-ahead by the FDA to start trials of its CAR-T immunotherapy UCART123 in patients with two haematological cancers.

The approval of Cellectis' Investigational New Drug (IND) application marks the first time that an 'off-the-shelf' or allogeneic CAR-T drug - which does not require cells to be harvested from patients unlike therapies developed by the likes of Novartis and Kite Pharma - has been cleared for clinical testing in the US.

UCART123 is a gene-edited CAR-T cell therapy that targets CD123 and will be tested in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN). The first patient dosing will start shortly, with the clinical trials conducted at Cornell and MD Anderson.

This is not the first time that one of Cellectis' CAR-T candidates has been tested in patients however. Another allogeneic CAR-T therapy - the CD19-targeting UCART19 - is already in trials in the UK being run by partners Servier and Pfizer.

Cellectis' UCART19 has shown positive effects in two leukaemia patients, although one suffered an episode of graft-versus-host disease (GVHD) which - while treated with steroids - indicates the possible toxicity with this new type of treatment. The two children have been disease-free for 18 and 12 months, respectively.

The IND approval for UCART123 "is a major milestone not only for the company but also for the medical community, global biotech and pharmaceutical industries at large," commented Dr Loan Hoang-Sayag, Cellectis' chief medical officer.

"Cellectis' allogeneic UCART products have the potential to create an important shift with regard to availability, and cost-effectiveness, to make these therapies widely accessible to patient population across the world," he added.

Novartis and Kite Pharma's autologous therapies are much further ahead in development, with first filings planned for this year but Cellectis believes its off-the-shelf treatment could be both quicker - and cheaper - to deliver to patients.

Article by
Phil Taylor

7th February 2017

From: Research, Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...